key: cord-1045390-9v9watl7
authors: Manhas, Sweeta; Anjali, Anjali; Mansoor, Sheikh; Sharma, Vikas; Ahmad, Ajaz; Rehman, Muneeb U.; Ahmad, Parvaiz
title: Covid-19 Pandemic and Current Medical Interventions
date: 2020-05-20
journal: Arch Med Res
DOI: 10.1016/j.arcmed.2020.05.007
sha: 396826c2c95de1744d9dc4ca08e82d9b945aca1f
doc_id: 1045390
cord_uid: 9v9watl7

Abstract First humanoid coronavirus was discovered in the middle of 1960s, the class of viruses are considered to be a huge threat. The first onset of human coronavirus, SARS (SARS-CoV) appeared in 2003 which spanned five continents having lethal effects on human population accompanied by The Middle East Respiratory Syndrome Coronavirus in 2012 with a death rate of 35%. The viruses remain a threat till date and are of serious concern since no vaccine or specified drug therapy has been approbated for treating human coronaviruses. The viruses became a pandemic worldwide with the emergence of Wuhan coronavirus (2019-nCoV). SARS-CoV2 viral manifestation poses a serious human life risk by causing acute lung injury and various respiratory outcomes and has become a global concern. High pathogenicity and transmission rate of the viral strain has become the spotlight of research community throughout the world. With the ongoing studies on viral structure and host interactions, the intricacy of the viral proteome structure and replication cycle proposes a need to explore our understanding of host factors playing role in viral multiplication cycle. This review provides insight into our prevalent perception of coronavirus-host interactions, structure of SARS-CoV2, receptor mediated entry of virus inside the human cells, ongoing clinical trials and drug therapies and treatments that are being used to combat COVID-19 targeting viral fusion, replication and its multiplication.

Named for their crown like spikes coronaviruses befit Coronaviridae family, subfamily coronavirinae, order Nidovirales. A positive sense single stranded RNA with 5'-cap and 3' polyA tail ranging from [26] [27] [28] [29] [30] [31] [32] Kbs forms the genetic material of coronaviruses (1) .Virion envelope is formed of spike (S) Arch Med Res E20_650 3 protein, membrane (M) protein and the envelope (E) protein, a helical nucleocapsid surrounds the viral genome. Adding to the three envelope proteins some coronaviruses also contain a hemagglutinin esterase (HE) protein (2) . The family of virus can infect different animal species along with humans and have been known over 50 years, with the discovery of first coronavirus in 1930 (3, 4) Four major subgroupings of the coronavirus family include alpha, β-infecting mammals; γ and δ-infecting birds predominantly. Human coronaviruses were first spotted amid-1960s. Amongst, seven different coronaviruses that can infect humans, the serotypes that can infect humans are of OC43-like and 229E type. Most common human coronaviruses belong to serotypes OC43 and 229E, both sharing common ancestor with bat coronavirus, (5) . With the divergence of closely associated bat coronaviruses and SARS-CoV in 1986, major outbreak of human coronaviruses causing fatal pneumonia started from the beginning of the 21 st century. With the spurt of SARS-CoV in 2003 spreading to five different continents with a 10% lethal rate and the incurrence of (MERS-CoV) with a fatality rate of 35% in 2012 (6) , outbreak of human coronavirus is considered to be a huge threat due to non-affirmation of any vaccine or specific drug therapy for treating human coronaviruses.

With the newly evolved Wuhan coronavirus , the situation becomes alarming all over the world. The viruses became a pandemic worldwide due to their potential to grow and high transmission rate posing a serious public health risk. On February 28 th , 2020 WHO raised the threat caused by this epidemic to the very high level (7) . Based on sequence analysis reports, the 2019-nCoV belongs to the group of β-coronaviruses possessing a characteristic coronavirus genome structure, the family have Bat-SARS-like (SL)-ZC45, Bat-SL ZXC21, SARS-CoV and MERS-CoV (8) . Ancestral linkages based on phylogenetic analysis of CoVs shows close relation between bat-SL-CoV ZC45 and bat-SL-CoV ZXC21 and COVID-19 as compared to SARS virus (8) . Coronavirus access host cells via its spike proteins, attached on viral envelope. The spike protein initiates receptor Control and Prevention. A diagnostic tool based on RT-PCR has also been described, the method intended to target various combinations of viral genome including Orf region, envelope, nucleocapsid, and RNA-dependent RNA polymerase (RdRp) genes (11) . For attachment to its host cell coronaviruses use homotrimers of the spike (S) glycoprotein, the S protein acts as a precursor of about 1300 amino acids and is synthesized as single polypeptide chain. S represents the main antigenic determinant at viral surface hence during viral infection S protein remains the target of neutralizing antibodies. Antigen-antibody interaction between viral and human cell proteins units makes it a prime focus towards vaccine designing (12) .

Based on sequencing and identification data SARS-CoV-2 was determined as a novel CoV having 88% sequence uniqueness with two bat-derived SARS-like CoV, 79.5% resemblance with SARS-CoV and 50% sequence homology to MERS-CoV (13) . Structural analysis of coronavirus genome encodes four major structural proteins ( (membrane) and the E (envelope) protein (1) . Different proteins encoded by vial genome regulate different functions, N protein is a multifunction protein regulating transcription processes and virion assembly efficiently. Trimeric S protein (each monomer 180 kDa) initiates viral entry into the target cell. COVID-19 spike (S) protein is a strongly determines viral transmission capacity and host tropism. S protein has a core domain and an external subdomain. Spike (S) protein consists of S1 and S2 subunit both involved in receptor binding and membrane fusion respectively (14) . The S1 subunit of spike protein folds as two independent domains both formed by the N and C terminal of S1 protein. Either of the two domains can serve as the receptor binding domain depending on the viral strain (15) . A serine and arginine rich domain involved in cell signalling known as SR-domain or linker region (LKR) separates the CTD from NTD. The LKR region has been proposed to bind with viral replicase-transcriptase complex (nsp3) and binding induced conformational changes in the LKR region are known to regulate intracellular localization of nucleocapsid (N) protein to the replication site (16) . ORF1ab, ORF3a, ORF6, ORF7a, ORF10 and ORF8 forms the non-structural protein part of the virus that are transcribed. ORF1a and ORF1b cleavage produces a set of non-structural proteins that assemble together to carry out viral replication and transcription processes (17) . Based on recent structural studies and homoly patterns SARS CoV-2 is found to exhibit a high affinity binding potential (10-20 fold) to human ACE2 than that of SARS-CoV owing to its high spread rate among human populations (14) .

Human coronaviruses access the host cells through a receptor mediated entry felicitated by specific receptors present on host cells. Aminopeptidase-N (CD13) and sialic acid as a receptor determinant have been identified as the most common routes for viral entry. The synergy between the spike region of virus and its receptor initiates the attachment of viral particles to the host cell. There are variations present in RBD sites within the S1 region of spike protein among different coronavirus strains. The interaction between the S protein and its receptor strongly determine the pathogenesis of a coronavirus. Host receptor binding is mediated by the N terminal domain-NTD of spike protein S1

subunit. The S1-NTD interacts with the glycans present on host cell receptor surface. A galectin fold mediating binding to sialic acids are thought to be commonly shared among all coronavirus S1-NTD (22) . Zoonotic β-coronaviruses (SARS-CoV) NTD shows a high binding affinity towards Angiotensin converting enzyme 2(ACE2) which serves as an operative receptor for viral entry (14) . On analysis, the receptor binding motif (RBM) in S protein revealed conserved amino acid residues between SARS-viral genome and SARS-CoV-2 genome showing 70% similarity, having nine common residues essential for receptor recognition suggesting same host cell receptor used by CoV-2 strain for cell entry (9) . A high propensity associated with ACE2 receptor and S1 domain of spike protein has been shown by (26) , 293T cells were used and transfected with ACE2 encoding plasmid, specific recognition was shown by cells transfected with plasmid expressing ACE2 towards S1-Ig. A similar study was conducted by (27, 28) to evaluate whether ACE2 is the common receptor used by (26, 28, 29) . Two main residues N479 and T487 have been associated in SARS-CoV to the recognition of the human ACE2 receptor. Intraspecies infection was possible due to Y442, L472, N479, D480, and T487 residues present in SARS-CoV. Some residues upon slight modification results in a stronger interaction with the receptors on human cell: L455, F486, Q493, and N501. In SARS-CoV-2, the N479 residues coincide to Q493 human cell receptor and T487 shows receptor recognition to N501 which are supported by the local environment present in the ACE2 receptor producing highly favourable electrostatic interactions for receptor binding (19) .

Protein-protein docking experiments performed by Micholas Smith and Jeremy C. Smith, 2020 indicates several differences in the sequences of SARS-CoV and COVID-19/SARS-CoV-2 but having similar binding affinities for the human hACE2 receptor. Based on early genome data of SARS-CoV-2, a close association has been linked between the spike protein of viral genome and specific receptors present on human cells. Therefore, ligand receptor binding upholds spike(S) glycoprotein mediated viral entry into the cell in SARS-C0V2 (30) (31) (32) . The RBD-spike protein acts as receptor recognition site that recognizes the receptors present on hACE2 (human angiotensin converting enzyme 2) regulated by TMPRSS2 proteases. Cryo-electron microscopy structures shows that two trimers of S protein can bind to n ACE2 homodimer simultaneously each through a Arch Med Res E20_650 9 monomer of (33). On successful binding of viral S protein RBD to its receptor (ACE2) there is significant reduction in ACE2 mRNA expression, the virus uses ACE2 receptors for entering their target cells, where it proliferates causing the upper respiratory tract infection and damages lung tissue triggering acute lung injury (34) . 

These are the antiretroviral drugs that can interfere in binding, fusion and virus entry to a human cell.

Some of drugs that are being used in case of COVID-19 are summarized here.

APN01 mimic the human ACE2, the main receptor used for virus protein S to enter host cell. The virus binds to soluble recombinant rhACE2 (APN01) instead of cellular ACE2 on surface of cell Arch Med Res E20_650 10 which then inhibits the virus action. APN01 also act as anti-inflammatory against acute respiratory distress syndrome (35, 36) . Due to dual action of mechanism, APN01 could be a potential drug against COVID-19.

Chloroquine and hydroxychloroquine, antimalarial drugs mainly used for treating rheumatoid arthritis and systemic lupus erythematosus (37) . Both chloroquine and hydroxychloroquine have shown in vitro activity against COVID-19 (18) . The mode of action for both drugs are same. It involves ACE2 cellular receptor inhibition by viral protein glycosylation (37) . It also increases pH of multivesicular bodies thus inhibits fusion of the virus. It also modulates immune system through attenuation of cytokines release (38) . Others mechanism of action may include: viral enzymes (DNA/RNA Polymerases) inhibition, and inhibition of transport of virus particle and its assembly. Chloroquine alone has potential benefit against COVID-19 pneumonia patients. The data has been evaluated for the same effect and it has shown significant results. Despite this, hydroxychloroquine has also shown significant response against COVID-19. An in vitro study from china also stated that hydroxychloroquine shows more efficacy than Chloroquine (20, 39) . Hydroxychloroquine also showed significant activity against COVID-19 given in combination with azithromycin (40) .

Arbidol Hydrochloride named Umifenovir, a broad-spectrum antiviral drug used for the treatment of human influenza infection and Arboviruses. Due to its hydrophobicity, it can form aromatic stacking Arch Med Res E20_650 11 interaction with some amino acids rendering it to act against viruses. It can also form stable interaction with plasma membrane of host cell which prevent viral entery (41, 42) . In a study it is stated that this drug is being used as a potential drug against COVID-19 combined with other HIV drugs in recent trials (13, 43) .

The replication of Covid-19 depends on the mechanism of viral RNA-dependent RNA polymerase (RdRp) which can be a direct target for various antiviral drugs such as Remdesivir (GS-5734),

Remdesivir, an antiviral drug, has been a high potential antiviral treatment till date suited against varied range of RNA viruses. The USFDA has approved its use in Covid-19 (www.usfda.gov/corona). Remdesivir is a monophosphate prodrug, an inhibitor of RNA polymerases which is an analogue to adenosine. Remdesivir incorporates into developing viral RNA, thereby terminates viral RNA chain and consequently put an end to replication of the viral genome (43, 44) . Remdesivir has been administered to severe covid-19 patients in Japan, United

Remdesivir were evaluated and data shows its efficiency against coronavirus (clinicaltrials.gov/NCT04323761).It has also shown a significant activity against coronavirus in preclinical trials Successful case reporting Remdesivir as an potent antiviral drug has been reported Arch Med Res E20_650 12 (45) .

Ribavirin is an analogue to guanosine, a broad-spectrum antiviral drug which suppress viral RNAdependent RNA polymerase activity. It involves several mechanism of action to inhibit replication of several virus (46) . It is analogue to guanine, preventing the binding of the correct nucleotides which leads to inhibition of viral RNA synthesis and mRNA capping (47) . It also acts a mutagen which leads to viral RNA termination and produces defective replicated viruses. It is earlier stated in vitro study that it also stimulates immunity through its immunomodulatory action and enhances the action of INF-α receptor and down-regulate the genes that are involved in interferon inhibition (48) .

Ribavirin has been certified against the treatment of COVID-19 (49) . The activity of Ribavirin against other CoVs like SARS and MERS support its potential against COVID-19 treatment (50).

Favipiravir-an antiviral treatment to influenza (51) . It has also shown great deal of anti-viral effects against a wide array of human-infecting RNA viruses. As Similar to Remdesivir, it targets the viral drug.

Protease inhibitors are antiviral drugs which after binding to viral proteases inhibits proteolytic cleavage of precursors protein required for production of infectious viral particles. Some Protease inhibitors are currently used in clinical and preclinical practices against COVID-19

Ivermectin, an anti-parasitic drug which has antiviral activity against different viruses including HIV, dengue, Zika and influenza (54) . It inhibits the interaction between viral protein and the importin (IMP) α/ß1 heterodimer, responsible for nuclear transport of viral protein (55) . In Monash Biomedicine Discovery Institute Scientist Dr. Kylie Wagstaff conducted a study and found a significant reduction in viral RNAs with a single dose of Ivermectin within 48 h.

Lopinavir and Ritonavir, a combination drug commonly name-HAART (highly active antiretroviral (43, 57) . Yet it has showed a negative result against COVID-19 but it is still possible that if this combination is combined with other drugs having high affinity for COVID-19 3CL pro , it may be useful for less severe cases of COVID-19.

Darunavir, HIV protease inhibitor which is synthetic nonpeptidic has been used in clinical trials against COVID-19. It competes with the active site of viral proteases via hydrogen bonds forms a inhibitor-enzyme complex thereby preventing cleavage of the polyproteins produces immature, noninfectious viral particles (58) . It could have significant virological and immunological outcomes.

Darunavir with Cobicistat is being given to patients under clinical trials against COVID-19 (ChiCTR; https://clinicaltrials.gov/ct2/show/NCT04252274). This drug might have a great advantage in coronavirus.

Along with sofosbuvir, an HCV NS5B polymerase inhibitor are combined used against the infection of chronic hepatitis C virus. These are NS5A inhibitors preventing HCV viral RNA replication and virion assembly (59) . The COVID-19 and hepatitis C virus shares similar replication mechanism therefore sofosbuvir has been tested in clinical trials against COVID-19 recently. In one of the in vitro study ,the virtual screening showed that velpatasvir in combination with sofosbuvir and ledipasvir in combination sofosbuvir may work against COVID-19 efficiently (8).

An antiviral and an anti-inflammatory drug used to treat autoimmune disease called rheumatoid arthritis, is a selectively reversible Janus Kinase (JAK) inhibitor which ultimately modulates gene expression in immunological cells (60) . This drug is being tested in clinical trials Phase 3 against COVID-19 and it showed efficacy for COVID-19.

These drugs categorised under immunosuppressive drug which inhibits various immunological effects. There are various drugs under clinical trials. Some of them are mentioned here within.

Tocilizumab Tocilizumab, an immune suppressant, used against rheumatoid arthritis (61) which binds to interleukin-6 receptors (soluble and membrane bound) competitively thereby inhibiting its immunological effects (Talluri www.preprints.org). It is suggested drug to treat COVID-19 patients in China shown its remarkable effectiveness and safety in clinical practice (www.reuters.com.). It is also seen Tocilizumab has efficacy over COVID-19 in severe cases in Italy and Naples (National Library of Medicine). Siltuximab, another humanized Monoclonal Antibody with same mechanism of action as Tocilizumab, this drug has been used in various clinical studies and found it as a potential 

The humanized anti-human C5 monoclonal antibody, a landmark in the anti-complement drug discovery act as complement-specific inhibitor works as inhibitor of C5 protein of the cascade complement system of the immune system thereby attenuating the inflammatory Response. The 

Safe and effective development of vaccines is urgently required to prevent this pandemic COVID-19 infection in the future. It requires a long time to prepare a vaccine as it is highly complex procedure involving various steps. There are several vaccines which are in process, are summarized here.

The vaccine developed by this approach adds a gene to viral proteins to stabilize them which can trigger the body's immune system thereby creating antibodies against it. The scientists from 

NVX-CoV2373 is a nanoparticles-based vaccine developed by Novavax and funded by CEPI 

Amongst the few emergency treatments to treat viral infection, doctors may consider the century old technique of supplying antibodies to critically ill patients from blood donors who have recovered. In this technique, the plasma is collected from the recovered person as it contains antibodies against COVID-19 developed while fighting with the virus. It is then used to treat affected COVID-19

patients. Once the COVID-19 patient has recovered, the blood sample is collected and the plasma is extracted out of it after proper checked for any other diseases. The extracted plasma contains antibodies against COVID-19 is then injected to a patient under treatment which further generates an immune response and protects against COVID-19 infections. This therapy has been already explored in some countries and showed improvement in some cases (64) .

The study of coronavirus structure and virus-host interactions using systematic screening approaches can help in the development of antiviral strategies that involves the use of specific inhibitors. Insights into the similarities between SARS-CoV2 and other coronaviruses along with the study of host directed approach could help in developing broad spectrum therapeutic strategies to treat viral • Introducing anti ACE2 antibodies

• Antibodies developed during SARS-CoV infection

Coronavirus envelope protein: current knowledge

Coronaviruses post-SARS: update on replication and pathogenesis

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus

Coronaviruses, a new group of animal RNA viruses

Mechanisms of coronavirus cell entry mediated by the viral spike protein

Origin and evolution of pathogenic coronaviruses

evaluation and treatment coronavirus

Treasure Island (FL): StatPearls Publishing

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. Version 2

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus

Novel coronavirus takes flight from bats?

Emergence of a novel coronavirus disease (covid-19) and the importance of diagnostic testing: Why partnership between clinical laboratories, public health agencies, and industry is essential to control the outbreak

Structural basis for human coronavirus attachment to sialic acid receptors

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Structure, function, and evolution of coronavirus spike proteins

Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein

The coronavirus nucleocapsid is a multifunctional protein

COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Host factors in coronavirus replication

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

Medical Microbiology 4 th edition: University of Texas Medical Branch at Galveston; Chapter 60

Regulation of stress responses and translational control by coronavirus

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

A pneumonia outbreak associated with a new coronavirus of probable bat origin

In silico study of the spike protein from SARS-CoV-2 interaction with ACE2: similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism

Repurposing therapeutics for covid-19: Supercomputer-based docking to the sars-cov-2 viral spike protein and viral spike protein-human ace2 interface

A Review on Probable Lysosomotropic Properties of Sodium Bicarbonate to Restrain Viral Entry of Coronavirus 2 (SARS-CoV-2)

Structural insights into coronavirus entry

Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target

Liver injury in COVID-19: management and challenges

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

A pilot clinical trial of recombinant human angiotensinconverting enzyme 2 in acute respiratory distress syndrome

New insights into the antiviral effects of chloroquine

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Arbidol: a broad-spectrum antiviral compound that Arch Med Res E20_650 27 blocks viral fusion

Arbidol as a broad-spectrum antiviral: an update

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Mechanism of action of ribavirin in the treatment of chronic hepatitis C

Mechanisms of action of ribavirin against distinct viruses

Ribavirin in the treatment of chronic hepatitis C

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Clinical outcomes among hospital patients with

Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses In vitro

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Computational studies of darunavir into HIV-1

necessary conditions for effective binding and the role of the flaps

Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase

COVID-19: combining antiviral and anti-inflammatory treatments

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

A Review of SARS-CoV-2 and the Ongoing Clinical Trials

The renaissance of complement therapeutics

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma